Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova
- PMID: 27059348
- PMCID: PMC7958309
- DOI: 10.1093/cid/civ1209
Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova
Abstract
Background: The Republic of Moldova was the first low- to middle-income country in the World Health Organization European Region to introduce rotavirus vaccine (July 2012). We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effectiveness (VE).
Methods: Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals in the capital city of Chisinau starting in September 2009. Monthly rotavirus admissions by age were examined before and after introduction of rotavirus vaccination using interrupted time-series analyses. We performed a case-control study of VE by comparing rotavirus case patients with test-negative controls.
Results: Coverage with at least 1 dose of vaccine increased from 35% in year 1 to 55% in year 2 for children <1 year of age. The percentage of hospital admissions positive for rotavirus fell from 45% in the prevaccine period to 25% (rate reduction, 36%; 95% confidence interval [CI], 26%-44%) and 14% (rate reduction, 67%; 95% CI, 48%-88%) in the first and second years after vaccine introduction, respectively, among children aged <5 years. Reductions were most pronounced among those aged <1 year. Significant reductions among cohorts too old to be vaccinated suggest indirect benefits. Two-dose VE was 79% (95% CI, 62%-88%) against rotavirus hospitalization and 84% (95% CI, 64%-93%) against moderate to severe rotavirus.
Conclusions: These results consistently point to profound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Republic of Moldova. Vaccine coverage was modest in these early years following introduction, so there remains potential for further disease reductions.
Keywords: Moldova; case-control; rotavirus; surveillance; vaccine effectiveness.
Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Conflict of interest statement
Figures




Similar articles
-
Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana.Clin Infect Dis. 2016 May 1;62 Suppl 2(Suppl 2):S200-7. doi: 10.1093/cid/ciw014. Clin Infect Dis. 2016. PMID: 27059357 Free PMC article.
-
Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.Clin Infect Dis. 2016 May 1;62 Suppl 2:S147-54. doi: 10.1093/cid/ciw045. Clin Infect Dis. 2016. PMID: 27059349
-
Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses.Clin Infect Dis. 2016 May 1;62 Suppl 2(Suppl 2):S213-9. doi: 10.1093/cid/civ1183. Clin Infect Dis. 2016. PMID: 27059359 Free PMC article.
-
A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact.Expert Rev Vaccines. 2018 Jul;17(7):593-606. doi: 10.1080/14760584.2018.1489724. Epub 2018 Jul 2. Expert Rev Vaccines. 2018. PMID: 29909693 Free PMC article. Review.
-
Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies.BMC Infect Dis. 2017 Aug 15;17(1):569. doi: 10.1186/s12879-017-2613-4. BMC Infect Dis. 2017. PMID: 28810833 Free PMC article.
Cited by
-
Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?Hum Vaccin Immunother. 2019;15(6):1215-1227. doi: 10.1080/21645515.2018.1553593. Epub 2019 Feb 8. Hum Vaccin Immunother. 2019. PMID: 30735087 Free PMC article. Review.
-
Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.Clin Infect Dis. 2016 May 1;62 Suppl 2(Suppl 2):S91-5. doi: 10.1093/cid/civ1015. Clin Infect Dis. 2016. PMID: 27059361 Free PMC article.
-
Rotavirus gastroenteritis surveillance in Azerbaijan, 2011-2016.Vaccine. 2018 Dec 14;36(51):7790-7793. doi: 10.1016/j.vaccine.2018.02.045. Epub 2018 May 18. Vaccine. 2018. PMID: 29784471 Free PMC article.
-
Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.Vaccine. 2019 Feb 4;37(6):798-807. doi: 10.1016/j.vaccine.2018.12.056. Epub 2019 Jan 11. Vaccine. 2019. PMID: 30639458 Free PMC article.
-
The rotavirus vaccine development pipeline.Vaccine. 2019 Nov 28;37(50):7328-7335. doi: 10.1016/j.vaccine.2017.03.076. Epub 2017 Apr 7. Vaccine. 2019. PMID: 28396207 Free PMC article. Review.
References
-
- Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136–41. - PubMed
-
- Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151–61. - PubMed
-
- Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2015; 385:430–40. - PubMed
-
- World Health Organization. Generic protocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of health care services for gastroenteritis in children. Geneva, Switzerland. 2002. Available at: http://apps.who.int/iris/bitstream/10665/67743/1/WHO_V-B_02.15_eng.pdf.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical